A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once‐Weekly DPP‐4 Inhibitor, Does Not Prolong the QTc Interval

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|5|5|383-392

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.5, Iss.5, 2016-09, pp. : 383-392

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lomitapide at Supratherapeutic Plasma Levels Does Not Prolong the QTc Interval—Results from a TQT Study with Moxifloxacin and Ketoconazole

By Darpo Borje   Ferber Georg   Zhou Meijian   Sumeray Mark   Sager Philip  

Annals of Noninvasive Electrocardiology, Vol. 18, Iss. 6, 2013-11 ,pp. : 577-589

Blackwell Publishing

Access to resources Recommend Favorite

Effects of Bilastine on T-wave Morphology and the QTc Interval: A Randomized, Double-Blind, Placebo-Controlled, Thorough QTc Study

By Graff Claus  

Clinical Drug Investigation, Vol. 32, Iss. 5, 2012-05 ,pp. : 339-351

Adis International

Access to resources Recommend Favorite

Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval

By Iannini Paul B  

Expert Opinion on Drug Safety, Vol. 1, Iss. 2, 2002-07 ,pp. : 121-128

Informa Healthcare

Access to resources Recommend Favorite

Testing for Positive Control Activity in a Thorough QTc Study

By Zhang Joanne  

Journal of Biopharmaceutical Statistics, Vol. 18, Iss. 3, 2008-05 ,pp. : 517-528

Taylor & Francis Ltd

Access to resources Recommend Favorite

Early Investigation of QTc Liability: The Role of Multiple Ascending Dose (MAD) Study

By Shah Rashmi R.  

Drug Safety, Vol. 35, Iss. 9, 2012-09 ,pp. : 695-709

Adis International

Access to resources Recommend Favorite